University and research institution
Appears in 5 stories
Lead institution for the NEOPRISM-CRC trial
A short course of immunotherapy before surgery kept every patient with a specific form of bowel cancer free of recurrence for nearly three years. In the NEOPRISM-CRC trial, 32 patients with MMR-deficient bowel cancer received pembrolizumab for up to nine weeks before surgery, instead of the usual post-operative chemotherapy.
Updated Yesterday
Collaborating institution
The microfluidic Axialtrode (mAxialtrode) is thinner than a sewing needle. Through a single soft fiber, it can record neural signals, inject drugs, and stimulate brain tissue with light at multiple depths at once.
Updated Sep 21
Led the epoxy-oxylipin inflammation study
Inflammation is supposed to stop once the threat passes. University College London researchers found the body's built-in brake for that process, and a drug can press it. In a controlled human trial, the drug sped up pain resolution and cut immune cells tied to chronic disease.
Updated Sep 13
Developed the AI system at the UCL Hawkes Institute
Rhys Hibbert, 48, went into surgery with an 11mm tumour pressing on the nerves that control his vision. He came out with what he calls 360-degree panoramic sight.
Updated Sep 7
Developer of BE-CAR7 base-edited therapy
Gene therapy killed Jesse Gelsinger in 1999. His death triggered FDA shutdowns and nearly ended the field.
Updated Jul 3
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
